Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on AnaptysBio (NASDAQ:ANAB) and maintains a $34 price target.
May 10, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reaffirmed an Outperform rating on AnaptysBio, with a price target of $34, indicating a positive outlook on the stock.
The reaffirmation of an Outperform rating and a maintained price target of $34 by a reputable analyst suggests a strong conviction in the stock's potential for growth. This positive analyst coverage is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100